S2/E112. What's Coming in Obesity Medicine? The Med Pipeline with Dr. Sean Wharton
What new medications are coming down the pipeline in Obesity Medicine? I explore the latest and greatest in obesity pharmacotherapy with my guest today, Dr. Sean Wharton.
Dr. Wharton is one of the leading Canadian researchers in Obesity Medicine. He is co-lead author of the Canadian Obesity Guidelines and the primary author of many of the clinical trials in bariatric medicine and type 2 diabetes. We discussed what is being studied in Phase 2 and 3 clinical trials in obesity management including:
- Semaglutide (Wegovy/Ozempic)
- Tirzepatide (Mounjaro/Zepbound)
- Retatrutide (GLP1, GIP, glucagon triple analogue)
- Cagrisema (amylin/GLP1 dual analogue)
- Bimagrumab (human monoclonal antibody)
- Cannabinoid-receptor antagonists (CB1)
- Orforglipron
- Oral GLP1 peptides
- Medications taken once monthly
**A small error that Dr. Wharton wanted to correct. The Amgen molecule discussed today is a GIPR antagonist, not a glucagon antagonist.
This week’s show brought to you by FRIDAY’S HEALTH.
If you’re in the USA looking for a healthcare provider and comprehensive obesity medicine program to support you in a science-backed, compassionate way, then check out Fridays Health. Each patient works with a medical provider as well as a team of coaches to pair medical treatment with effective behavioural support. Use code HIGH to get $20 USD off the first month of your membership.
FIND DR. SEAN WHARTON
Instagram @drseanwharton
Clinical Trials https://whartonmedicalclinic.com/clinical-trials/
FOLLOW SASHA
Instagram - https://www.instagram.com/sashahighmd/
Tiktok - https://www.tiktok.com/@sashahighmd
WORK WITH ME
Join my Weight Loss Coaching Program for women, Best Weight https://www.sashahighmd.com/bestweight
Recover Strong for Binge Eating - https://www.sashahighmd.com/bed
Ontario OHIP-covered Obesity Medicine https://www.highmetabolicclinic.com
